Generic medications are approved by the FDA because they have the same safety and effectiveness profiles as the name-brand or ...

Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

Some Canadians will be able to buy brand-name GLP-1 drug Ozempic at a reduced price, Danish drugmaker Novo Nordisk said in a statement Tuesday. The move comes as two generic versions of Ozempic and ...

The generic versions will give patients and healthcare providers access to “affordable alternatives" to brand name formats, says Canadian drug manufacturer, Apotex You can save this article by ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

The Trump administration has expanded TrumpRx to include more than 600 generic medications — a significant scale-up from the platform’s original focus on branded drugs under most-favored-nation ...

The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...

WASHINGTON, May 18 (Reuters) - U.S. President Donald Trump said on Monday that TrumpRx.gov, a government-backed website that lists discounted prescription drugs, will begin featuring generic medicines ...

India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Limited time: Save 25% on NBC News subscription Get ...

The chief executive of generic-drug maker Sandoz SDZ0.35%increase; up pointing triangle Group expects the market for unbranded versions of popular weight-loss medicines to be big. Just how big, though ...

Patent expiry across API, formulation, and device IP is expected to catalyze biosimilar competition, expanding access while compressing pricing across pharmaceutical and device value chains.